Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of subcutaneous JS005 in adults with active non-radiographic axial spondyloarthritis in China
CTR20212214Phase 2Suspended
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of roconkibart in non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Dec 2021; status: suspended.
02
Drugs
roconkibart
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on CTR20212214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212214.